d3 Medicine LLC, an expert biopharmaceutical strategic advisory company, and Viroclinics Biosciences BV have signed a non-exclusive Memorandum of Understanding on the 1st of July 2014 to provide biopharmaceutical customers with an integrated solution to accelerate the preclinical and clinical development of drugs, biologicals, vaccines and diagnostics targeting viral infectious diseases.
The alliance leverages the strengths of the two companies and will offer services that enable biopharmaceutical customers to accelerate virological investigational agents through preclinical and clinical development to market launch.


CR2O is a recently established research organization that focusses on managing and operating clinical trials for vaccine-, drug-, and diagnostics development by industry and public organizations. CR2O closely collaborates with leading clinics and research centers in Europe. Erasmus Medical Center, including Rotterdam University Hospital, is an important liaison to CR2O. CR2O also closely collaborates with the Dutch University Hospitals of Amsterdam, Leiden, Groningen and Nijmegen and their affiliated peripheral hospitals. Together with Viroclinics, CR2O participates in a worldwide network of virology laboratories. Collectively this dynamic clinical and research infrastructure provides CR2O with a unique position as a new service provider (i.e. research and expertise center) entering the field of clinical trials for infectious disease interventions, to test new generations of vaccines, drugs, and diagnostic approaches.